DEA Reschedules FDA-Approved & State-Licensed Medical Marijuana Products; Hearing Set On Broader Marijuana Reclassification

The U.S. Department of Justice (DOJ) and the Drug Enforcement Administration (DEA) issued an order on April 23, 2026, moving marijuana-based products approved by the U.S. Food and Drug Administration (FDA), as well as products distributed under qualifying state-issued medical marijuana licenses, from Schedule I to Schedule III under the Controlled Substances Act.

The DEA and DOJ will also hold an expedited administrative hearing on June 29, 2026, to consider broader federal rescheduling of marijuana from Schedule I to Schedule III.

Under the Controlled Substances Act, substances are categorized based on accepted medical use and abuse . . .